ClinicalTrials.gg
RecruitingNCT07221877Updated Nov 10, 2026

A Study to Evaluate the Effect of KarXT on Urological Safety

A Phase 4 interventional study of Xanomeline/trospium chloride in Schizophrenia, sponsored by Bristol-Myers Squibb. Recruiting at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 10, 20267 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Planned enrollment
17th of 20
60 · median 178
Started
2026
with 4 others
Phase 4
3 of 20
3 open now
Registered
16th of 20
by date
Lead sponsor
4 of 20
Bristol-Myers Squibb

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 17th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 4, and was the 16th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female participants (age 18 to 65 years of age, with a primary diagnosis of schizophrenia based on psychiatric evaluation () and confirmed by MINI (v 7.0.2).
  • Participants must have a PANSS total score ≤ 80 and CGI-S score ≤ 4, at screening and baseline, and a ≥18 and ≤ 40 kg/m2.
  • Participants must be willing and able to discontinue all antipsychotic medications prior to the baseline visit and be willing and able to comply with protocol requirements.

Exclusion criteria

Exclusion Criteria

  • Participants with newly diagnosed schizophrenia, any other disorder diagnosed within the past 12 months, alcohol or drug use disorder within the past 12 months, history/presence of disease or disorder that would jeopardize participant safety or validity of study results.
  • Participants at risk for suicidal behavior, as well as individuals who are pregnant or breastfeeding, will be excluded from the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline/trospium chloride

Interventions

  • DrugXanomeline/trospium chloride

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: KarXT, BMS-986510

06

What researchers measure

Primary outcomes

  1. Change from baseline in voiding dynamics (Qmax) over time

    Time frame: Up to 12 months

  2. Change from baseline in post-void residual volume (PVR) over time

    Time frame: Up to 12 months

Secondary outcomes

  1. Number of participants with a change from baseline in urinalysis parameters over time

    Time frame: Up to 12 months

  2. Change from baseline in IPSS over time

    Time frame: Up to 12 months

  3. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 12 months

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 12 months

  5. Number of participants with Adverse Events (AEs)

    Time frame: Up to 12 months

  6. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to 12 months

  7. Number of participants with Serious AEs (SAEs)

    Time frame: Up to 12 months

  8. Number of participants with suicidal ideation or behavior

    Time frame: Up to 12 months

07

Study locations

15 of 16 sites recruiting
  • Pillar Clinical Research- Little Rock
    Little Rock, Arkansas 72204, United States
    Recruiting
    • Leslie Smith, Site 0017 · Contact501-350-3285
  • Clinical Innovations, Inc. dba CITrials
    Bellflower, California 90706, United States
    Recruiting
    • Gerald Maguire, Site 0007 · Contact951-300-4924
  • Inland Psychiatric Medical Group, Inc
    Chino, California 91710, United States
    Recruiting
    • Nandita Puchakayala, Site 0018 · Contact909-488-9116
  • CenExel CNS - Garden Grove
    Garden Grove, California 92845, United States
    Recruiting
    • David Walling, Site 0006 · Contact714-799-7799
  • ATP Clinical Research
    Orange, California 92866, United States
    Recruiting
    • Gustavo Alva, Site 0016 · Contact949-354-5353
  • Collaborative Neuroscience Research, LLC
    Torrance, California 90504, United States
    Recruiting
    • Lara Shirikjian, Site 0019 · Contact310-523-4200
  • Kinetic Clinical Research
    West Covina, California 91790, United States
    Recruiting
    • Austina Cho, Site 0020 · Contact714-999-6688
  • Health Synergy Clinical Research
    Boynton Beach, Florida 33426, United States
    Recruiting
    • Mohammad Nisar, Site 0004 · Contact786-831-7303
  • Innovative Clinical Research
    Lauderhill, Florida 33319, United States
    Recruiting
    • Rishi Kakar, Site 0003 · Contact786-512-4106
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
    Recruiting
    • John Sonnenberg, Site 0005 · Contact773-968-9868
  • Pillar Clinical Research -Chicago
    Chicago, Illinois 60641, United States
    Recruiting
    • Roueen Rafeyan, Site 0010 · Contact312-865-6336
  • IMA Clinical Research Las Vegas
    Las Vegas, Nevada 89102, United States
    Recruiting
    • Mustafa Rawaf, Site 0013 · Contact702-527-7401
  • Hassman Research Institute Marlton Site
    Marlton, New Jersey 08053, United States
    Recruiting
    • Elan Cohen, Site 0002 · Contact267-981-8911
  • Adams Clinical Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Cassie Blanchard, Site 0014 · Contact631-252-0769
  • Local Institution - 0001
    Austin, Texas 78754, United States
    Not yet recruiting
    • Site 0001 · Contact
  • Adams Clinical Dallas
    DeSoto, Texas 75115, United States
    Recruiting
    • Benji Kurian, Site 0015 · Contact214-497-3151
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 28, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 4 sites removed
Show 7 added (7 United States)
  • Local Institution - 0018 · Redlands, United States
  • Collaborative Neuroscience Research, LLC · Torrance, United States
  • Local Institution - 0020 · West Covina, United States
  • Health Synergy Clinical Research · Boynton Beach, United States
  • Adams Clinical Dallas · DeSoto, United States
  • Inland Psychiatric Medical Group, Inc · Chino, United States
  • Kinetic Clinical Research · West Covina, United States
Show 4 removed
  • Health Synergy Clinical Research · West Palm Beach, United States
  • InSite Clinical Research · DeSoto, United States
  • Local Institution - 0018 · Redlands, United States
  • Local Institution - 0020 · West Covina, United States
across 2 updates, Oct 19, 2026 – Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Clinical Innovations, Inc. dba CITrials · Bellflower, United StatesContact •••4999→•••4924
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Inland Psychiatric Medical Group, Inc · Chino, United States
    • Kinetic Clinical Research · West Covina, United States
    Show 2 removed
    • Local Institution - 0018 · Redlands, United States
    • Local Institution - 0020 · West Covina, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Clinical Innovations, Inc. dba CITrials · Bellflower, United StatesContact •••4999→•••4924
    + 1 other change: verification date
  2. Oct 19, 2026
    5 sites added, 2 sites removed
    Show 5 added (5 United States)
    • Local Institution - 0018 · Redlands, United States
    • Collaborative Neuroscience Research, LLC · Torrance, United States
    • Local Institution - 0020 · West Covina, United States
    • Health Synergy Clinical Research · Boynton Beach, United States
    • Adams Clinical Dallas · DeSoto, United States
    Show 2 removed
    • Health Synergy Clinical Research · West Palm Beach, United States
    • InSite Clinical Research · DeSoto, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07221877
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Jan 20, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion